PPARGC1A and Myocardial fibrosis: Additionally, by activating the AMPK/PGC-1α pathway, AS-IV enhances myocardial glucose and fatty acid metabolism and influences metabolic reprogramming and inflammation, thereby reducing myocardial fibrosis and improving cardiac function.